The Brazil IP office president’s efforts to reduce one of the world’s worst backlogs have been derailed by recession. However, he hopes to take proactive measures, despite sceptical IP practitioners inside and outside Brazil and the controversy over double examination of pharmaceutical patents. Michael Loney reports
Unlock this article.
The content you are trying to view is exclusive to our subscribers.